Anti Phospholipid Antibody (APL) - IgM

Immunity

Report in 12Hrs

At Home

No Fasting Required

Details

This test specifically measures IgM-type antibodies, which can sometimes appear before or alongside IgG-type in autoimmune disorders or during acute episodes

₹499₹825

40% OFF

Anti Phospholipid Antibody (APL) - IgM Test Information Guide

Why is it done?
- Detects IgM class immunoglobulin antibodies against phospholipid antigens, which are involved in antiphospholipid syndrome (APS)
- Identifies patients at risk for thrombosis (blood clots), recurrent miscarriages, and other thrombotic complications
- Used when patients present with unexplained venous or arterial thrombosis
- Evaluates patients with recurrent pregnancy loss or obstetric complications
- Assists in diagnosis of autoimmune conditions, systemic lupus erythematosus (SLE), and other connective tissue disorders
- Performed when patients have unexplained prolonged activated partial thromboplastin time (aPTT)
- Typically ordered during acute clinical presentations or as part of initial workup for thrombotic events
Normal Range
- Normal Result: Negative or <12 IgM GPL Units (IgM Phospholipid Units)
- Borderline/Low Positive: 12-40 IgM GPL Units
- Moderate to High Positive: >40 IgM GPL Units
- Units of Measurement: IgM Glycerol Phosphate (GPL) units per milliliter
- Interpretation: Negative results indicate absence of IgM anti-phospholipid antibodies. Positive results (>12 units) suggest the presence of these antibodies and indicate increased thrombotic risk. Higher values (>40 units) typically indicate more significant clinical relevance, though clinical symptoms and repeat testing are necessary for diagnosis of antiphospholipid syndrome
Interpretation
- Negative Result (<12 IgM GPL Units): Indicates absence of IgM anti-phospholipid antibodies; thrombotic risk from this specific antibody is considered low; does not exclude IgG antibodies which may still be present
- Borderline Positive (12-40 IgM GPL Units): Suggests presence of IgM anti-phospholipid antibodies but below high-risk threshold; repeat testing recommended at 12 weeks to confirm persistence; repeat positivity combined with clinical symptoms supports APS diagnosis
- High Positive (>40 IgM GPL Units): Strongly indicates presence of significant anti-phospholipid antibodies; associated with increased thrombotic risk and clinical manifestations of APS; requires clinical correlation and often additional testing; repeat testing recommended
- Factors Affecting Results:
- IgM antibodies may be transient and associated with acute infections (viral or bacterial); acute illness or recent vaccination can produce false positives that resolve within weeks
- Persistent positive results (>12 weeks apart) are more clinically significant than single positive results
- IgM antibodies typically indicate more recent immune response compared to IgG antibodies
- Clinical symptoms and findings must correlate with antibody presence for APS diagnosis
- Anticoagulation therapy (warfarin or heparin) does not affect antibody detection
- Clinical Significance:
- Positive IgM antibodies support diagnosis of antiphospholipid syndrome when clinical criteria are met (thrombosis or pregnancy morbidity)
- May be associated with other autoimmune conditions including systemic lupus erythematosus and rheumatoid arthritis
- IgM positivity can occur with acute infections and may resolve without pathological significance
Associated Organs
- Primary Organ Systems Involved:
- Vascular System: Blood vessels throughout the body are primary targets; thrombosis can occur in veins and arteries
- Hematologic System: Platelets and coagulation factors affected; increased risk of bleeding or clotting
- Reproductive System: Placental infarction and inadequate placental function; associated with pregnancy complications
- Immune System: Autoimmune response with production of pathogenic antibodies
- Associated Medical Conditions:
- Antiphospholipid Syndrome (APS): Primary condition; includes both primary and secondary APS
- Systemic Lupus Erythematosus (SLE): Most common associated autoimmune disease; 30-40% of SLE patients have APL antibodies
- Rheumatoid Arthritis: Frequently associated with APL antibodies; increased thrombotic risk
- Antiphospholipid Syndrome with Thrombotic Manifestations: Deep vein thrombosis, pulmonary embolism, arterial thrombosis
- Obstetric APS: Recurrent miscarriage, fetal loss, premature birth, intrauterine growth restriction, placental insufficiency
- Sjögren's Syndrome: Secondary autoimmune condition; APL antibodies may be present
- Infectious Diseases: Transient APL antibodies with HIV, hepatitis C, syphilis, and other infections
- Potential Complications and Risks:
- Venous Thromboembolism: Deep vein thrombosis and pulmonary embolism; recurrent episodes possible
- Arterial Thrombosis: Stroke, myocardial infarction, peripheral arterial disease
- Catastrophic APS: Rare but life-threatening condition with multi-organ thrombosis; high mortality rate
- Recurrent Fetal Loss: Multiple consecutive miscarriages or unexplained fetal death
- Thrombocytopenia: Low platelet count with increased bleeding risk
Follow-up Tests
- Confirmatory Testing:
- Anti-Phospholipid Antibody (APL) - IgG: Testing for IgG antibodies recommended; may be more persistent and clinically significant than IgM
- Repeat APL-IgM Testing at 12 Weeks: Confirmation of persistent positivity required for APS diagnosis; single positive result insufficient
- Anti-Cardiolipin Antibodies (ACA) IgM and IgG: Targets different phospholipid epitopes; provides additional diagnostic information
- Anti-Beta-2 Glycoprotein I (Anti-β2GPI) Antibodies: Specific for APS; higher specificity and clinical relevance than APL
- Lupus Anticoagulant (LAC) Testing: Functional assay; positive LAC associated with higher thrombotic risk
- Coagulation and Thrombotic Evaluation:
- Activated Partial Thromboplastin Time (aPTT): Baseline test; may be prolonged if lupus anticoagulant present
- Prothrombin Time (PT)/INR: Assess overall coagulation status
- Platelet Count: Evaluate for thrombocytopenia associated with APS
- Autoimmune and Systemic Disease Screening:
- Antinuclear Antibodies (ANA): Screen for SLE and other autoimmune disorders
- Anti-dsDNA and Anti-Smith Antibodies: Specific for systemic lupus erythematosus
- Complement Levels (C3, C4): Assess disease activity and immune complex burden
- Rheumatoid Factor and Anti-CCP: Evaluate for rheumatoid arthritis
- Imaging and Diagnostic Studies:
- Venous or Arterial Ultrasound/Doppler: Screen for thrombosis if clinically indicated
- CT Pulmonary Angiography (CTPA): Evaluate for pulmonary embolism if signs/symptoms present
- Electrocardiography (ECG): Baseline cardiac assessment; may show evidence of prior thrombotic events
- Monitoring Frequency:
- Initial Positive Result: Repeat testing at 12 weeks for confirmation
- Confirmed APS Diagnosis: Annual follow-up or more frequently if on anticoagulation therapy
- During Pregnancy with APS: Closer monitoring recommended (every 4-8 weeks) given increased thrombotic and obstetric risks
- After Thrombotic Event: Serial testing may be warranted depending on clinical course and anticoagulation response
Fasting Required?
- Fasting Requirement: NO
- Fasting is not required for anti-phospholipid antibody testing
- Patients may eat and drink normally before blood collection
- Medications:
- No medications need to be stopped or avoided for this test
- Anticoagulant medications (warfarin, heparin, direct oral anticoagulants) do NOT interfere with antibody detection and should be continued
- Aspirin or other antiplatelet agents should be continued as prescribed
- Patient Preparation:
- No special preparation required
- Bring insurance card and identification to collection facility
- Inform phlebotomist of any recent infections, vaccinations, or acute illnesses as these may affect results
- For confirmatory testing at 12 weeks, ensure similar collection conditions and timing
- Blood sample collected via venipuncture into appropriate collection tube (typically EDTA or citrate tube depending on laboratory protocol)

How our test process works!